- 1 Variations in state-level SARS-COV-2 testing recommendations in the United States,
- 2 March-July 2020

3

5

8

- 4 Stephanie R. Perniciaro & Daniel M. Weinberger
- 6 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New
- 7 Haven, CT, United States.
- 9 Abstract
- 11 Background: Testing recommendations for COVID-19 in the United States varied by
- state and over time in the spring and summer of 2020.
- Methods: We compiled data about COVID-19 testing, cases, and deaths, and excess
- pneumonia + influenza + COVID-19 deaths to assess relationships between testing
- recommendations, per capita tests performed, epidemic intensity, and excess mortality
- during the early phase of the COVID-19 pandemic in the United States.
- 17 Results: As of July 2020, 16 states recommended testing asymptomatic members of the
- general public. The rate of COVID-19 tests reported in each state correlates with more
- inclusive testing recommendations and with higher epidemic intensity. Higher per capita
- testing was associated with more complete reporting of COVID-19 deaths, which is a
- 21 fundamental requirement for analyzing the pandemic.

Conclusions: Reported deaths due to COVID-19 likely represent an undercount of the

true burden of the pandemic. Coordinated, consistent guidelines for COVID-19 testing

should be a high priority for state and national health systems.

Background

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

SARS-CoV-2, the virus that causes COVID-19, was declared a global pandemic by the

World Health Organization in March 2020. Worldwide, responses to the pandemic have

varied and had varying success. In the United States, each state determined testing

guidelines, lockdown procedures, and reopening procedures individually.² The Centers

for Disease Control and Prevention also maintained testing recommendations and

guidelines, but states and localities were largely responsible for their own policies.³ The

COVID-19 pandemic in the United States is ongoing, costing around 150,000 lives by

the end of July 2020.4

Testing for COVID-19 has been a continual hurdle in the United States. 5 Supply chain

issues, doubts about testing accuracy and methodology, and conflicting guidance from

federal, state and local officials about testing have all interfered with testing efforts.8

State governments and health departments established testing guidelines in March

2020, which were sometimes augmented by local governmental health departments.9

The turnaround time for test results has been strained, 10 and resources for individuals to

sustain their household resources while remaining isolated or guarantined while

awaiting the result of a test have not been widely available.¹¹

Here we describe the changing recommendations for COVID-19 testing to the general public in the United States in the spring and summer of 2020 and the consequences of these changes for obtaining accurate statistics about the pandemic.

Methods

The objective of this analysis was to establish whether varying the state-level COVID-19 testing guidelines had any impact on the actual number of tests performed, and whether the number of tests performed was related to the rate of recognizing COVID-19 deaths as a cause of excess mortality (reported COVID-19 deaths/excess pneumonia + influenza+ COVID-19 (PIC) deaths). COVID-19 testing guidelines were documented from the websites of the departments of health in each of the 50 states and the District of Columbia once monthly from March-July 2020 (Supplemental Table 1). We ranked recommendations to tests by the general public (as opposed to members of specific named risk groups) by assigning 0= criterion not specified, 1= accessible to people with a negative influenza test, 2= accessible to people with symptoms consistent with COVID-19 illness, 3= accessible to anyone, including asymptomatic people.

Correlations between testing recommendation score, tests per capita, and percentage of positive tests were analyzed with Spearman correlation tests.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

We used a generalized additive model (negative binomial link) to assess the completeness of death reporting. The outcome variable was the number of reported COVID-19 deaths in each state and month. The number of excess PIC deaths was included as an offset term, so this effectively models the ratio of reported COVID-19 deaths/excess PIC deaths. The *per capita* testing rate in each state and month was included as a penalized spline. Uncertainty in the estimates of excess PIC deaths were ignored in these analyses, and excess PIC deaths were constrained to be greater than or equal to the reported COVID-19 deaths. The model was fit using the package "mgcv" in R.

We also evaluated relationships between the number of COVID-19 tests performed per capita, testing recommendations score, and epidemic intensity (defined as excess PIC deaths¹² per capita) using a negative binomial regression model. Total COVID-19 tests performed in each state was the outcome variable, offset by the log of the total population of each state, with the testing recommendations score (categorical) and the log of epidemic intensity as the independent variables.

The number of excess PIC deaths per state and the reported number of COVID-19 deaths were obtained from a repository describing excess deaths during the COVID-19 (https://github.com/weinbergerlab/excess pi covid). 12 outbreak Final were obtained August 15, 2020. Positive tests and the overall number of tests in each state collected were from the website of The COVID Tracking Project (https://covidtracking.com/). Population data were taken from the United States Census

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

Bureau's 2019 estimates. R (R: A language and environment for statistical computing, version 3.6.1. R Foundation for Statistical Computing, Vienna, Austria, https://www.Rproject.org/.) was used for statistical analyses. Results State Testing Guidelines From March to July 2020, recommendations of COVID-19 testing for the general public varied between states and over time (Figure 1), as did testing prioritization for identified risk groups (Supplemental Figure 1). The earliest-available state-level data ranged from March 1 (in Michigan, Rhode Island, and Washington) to March 12 (in Massachusetts), while the remaining 47 states began reporting COVID-19 data between March 4 and March 7. March data included all March dates – April 4; April data included April 5 – May 2; May data included May 3 – June 6; June data included June 7 – July 4: July data included records from July 5 – 31. As of July, 16 states recommended that asymptomatic members of the general public be tested for COVID-19. 9 states actively recommended against the testing of asymptomatic people; 3 of which then reversed this recommendation in July. South Dakota also recommended against seeking a test if people were experiencing symptoms, citing the lack of effective COVID-19 therapy as a contraindication for testing. Most states (35/51) changed their testing recommendations twice between

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

March and July. Only Oklahoma did not change their testing criteria, though the state health department website specifies that private testing facilities have their own criteria. Factors associated with higher rates of testing Reported COVID-19 tests per capita increased steadily, though unevenly, from March to June, while the percentage of positive tests varied widely between states (Figure 2, 3). States with more permissive testing recommendations had a lower percentage of positive tests (rho -0.22, 95% CI -0.34, -0.11), reflecting the inclusion of lower risk individuals in the testing pool. The minimum percentage of positive tests for a single month was 0.8% in May in Alaska; the maximum was 47% in April in New Jersey. In a multivariate model, both more inclusive testing recommendations and higher epidemic intensity were associated with higher rates of testing. Testing intensity and completeness of death reporting The completeness of recording deaths as due to COVID-19 was related to the rate of testing. (Figure 4). This was particularly true in the first months of the pandemic when testing levels were low relative to the intensity of the epidemic; in later months, the level of testing was high and had little influence on the difference between reported COVID-19 deaths and excess PIC deaths. Discussion

In order to obtain accurate statistics on the COVID-19 pandemic, viral testing needs to scale with epidemic intensity. Particularly in the early months of the pandemic, restrictive state-level testing recommendations and difficulties in accessing tests resulted in inadequate testing levels.⁵ This was manifest in higher viral positivity rates and greater differences between reported COVID-19 deaths and excess PIC deaths. From March-May, testing per capita and completeness of mortality data both increased, though afterwards this apparent relationship became less clear. It is possible that other characteristics of healthcare systems in each state influenced both the testing rates and completeness of death reporting (i.e. supply chain or personnel issues). The variation in data completeness seen in July may be due to reporting delays, and thus might decrease as mortality data are updated. Expanded access to testing can play a critical role in obtaining an accurate picture of the progression of the epidemic.

This study has certain limitations. Changes in completeness of death reporting could be influenced by other factors that might also vary over time, such as state-level guidelines for coding deaths as due to COVID-19. The viral testing criteria established by state health departments are sometimes superseded by local governments or private clinics. The testing data counts tests, not individuals, so people tested multiple times will be included multiple times.

Conclusions

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

The patchwork of state-level testing guidelines is associated with local variations in testing intensity, and these variations have consequences for the completeness of data on key indicators of the severity and progression of the pandemic. More coordinated national guidance could strengthen the pandemic tracking and response. List of Abbreviations PIC: pneumonia + influenza + COVID-19 CI: confidence interval **Declarations** Ethics approval and consent to participate: Not applicable Consent for publication: Not applicable Availability of data and materials: The datasets generated and/or analysed during the available Tracking current study are in the COVID Project repository PIC (https://covidtracking.com/), the excess mortality repository (https://github.com/weinbergerlab/excess pi covid), and on the websites of the state health departments (all of which appear in Supplemental Table 1). Competing interests: SRP has received travel fees from Pfizer unrelated to this manuscript. DMW has received consulting fees from Pfizer, Merck, GSK, and Affinivax for work unrelated to this manuscript and is Principal Investigator on a grant from Pfizer to Yale University on a project unrelated to this manuscript

- Funding: SP was supported by a NIH T32 training grant, award number
- 181 2T32Al007210-36A1 (MPI).
- Authors' contributions: SP conceived of the study, extracted the data, ran the
- analyses, and wrote the first draft of the paper. DMW contributed to the design of the
- study and revisions of the manuscript and plotting.
- Acknowledgements: We would like to thank the state health departments in the United
- States and the District of Columbia and the COVID Tracking Project for providing data
- used for these analyses.
- Authors' information: stephanie.perniciaro@yale.edu
- 190 References

- 191 1. WHO Director-General's opening remarks at the media briefing on COVID-19 11
- March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-
- opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
- 2. Schuchat, A. Public Health Response to the Initiation and Spread of Pandemic
- 195 COVID-19 in the United States, February 24–April 21, 2020. MMWR Morb. Mortal.
- 196 Wkly. Rep. **69**, (2020).
- 197 3. Haffajee, R. L. & Mello, M. M. Thinking Globally, Acting Locally The U.S.
- 198 Response to Covid-19. *N. Engl. J. Med.* **382**, e75 (2020).
- 199 4. US Historical Data. The COVID Tracking Project
- 200 https://covidtracking.com/data/national.
- 5. Shear, M. D. et al. The Lost Month: How a Failure to Test Blinded the U.S. to Covid-
- 202 19. The New York Times (2020).

203 6. CNN, P. L. Hogan: Maryland protected coronavirus tests it secured from South Korea 'like Fort Knox'. CNN https://www.cnn.com/2020/04/30/politics/larry-hogan-204 coronavirus-masks-national-quard/index.html. 205 206 7. Walsh, J. D. How Reliable Are COVID-19 Tests? *Intelligencer* 207 https://nymag.com/intelligencer/2020/06/how-accurate-are-covid-19-tests.html 208 (2020).8. Remarks by President Trump After Tour of the Centers for Disease Control and 209 Prevention | Atlanta, GA. The White House https://www.whitehouse.gov/briefings-210 211 statements/remarks-president-trump-tour-centers-disease-control-prevention-212 atlanta-ga/. 9. Georgia Governor And The Mayor Of Atlanta In Turf War Over COVID-19 213 214 Restrictions. NPR.org https://www.npr.org/sections/coronavirus-liveupdates/2020/07/10/889930319/georgia-governor-and-the-mayor-of-atlanta-in-turf-215 war-over-covid-19-restrictions. 216 217 10. 'It's Like Having No Testing': Coronavirus Test Results Are Still Delayed - The New York Times. https://www.nytimes.com/2020/08/04/us/virus-testing-delays.html. 218 11. HaddenKristie et al. Addressing Homelessness and Covid-19 Quarantine: A 219 Streamlined Assessment and Referral Process. NEJM Catal. Innov. Care Deliv. 220 (2020).221 12. Weinberger, D. M. et al. Estimation of Excess Deaths Associated With the COVID-222 19 Pandemic in the United States, March to May 2020. JAMA Intern. Med. (2020) 223

doi:10.1001/jamainternmed.2020.3391.

224

Supplementary Materials

Supplemental Table 1. State health department websites, used as the source to determine state-level COVID-19 testing guidelines.

State	Source(s)
AL	https://www.alabamapublichealth.gov/covid19/patients.html
AK	http://dhss.alaska.gov/dph/Epi/id/SiteAssets/Pages/HumanCoV/AKCOVIDTestingGuidance.pdf
	https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/infectious-
AZ	diseases-services/coronavirus/arizona-state-public-health-laboratory-testing-matrix.pdf
	https://www.healthy.arkansas.gov/programs-services/topics/covid-19-guidance-for-getting-
AR	<u>tested</u>
	https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Expanding-Access-to-Testing-
CA	<u>Updated-Interim-Guidance-on-Prioritization-for-COVID-19-Laboratory-Testing-0501.aspx</u>
СО	https://covid19.colorado.gov/covid-19-in-colorado/about-covid-19/testing-for-covid-19
CT	https://portal.ct.gov/Coronavirus/Covid-19-Knowledge-Base/COVID-19-Testing
DE	https://coronavirus.delaware.gov/testing/testing-frequently-asked-questions/
DC	https://coronavirus.dc.gov/testing
FL	https://floridahealthcovid19.gov/health-care-providers/
GA	https://dph.georgia.gov/covid-19-testingdirect-patient-lines
HI	https://health.hawaii.gov/coronavirusdisease2019/for-clinicians/evaluating-puis/
ID	https://rebound.idaho.gov/wp-content/uploads/testing-recommendations.pdf

	https://www.dph.illinois.gov/topics-services/diseases-and-conditions/diseases-a-z-							
IL	list/coronavirus/health-care-providers							
	https://www.coronavirus.in.gov/files/IN-	https://www.coronavirus.in.gov/files/IN-COVID-						
IN	COVID-19_FAQforPublic%207.3.20.pdf	19 FAQforPublic%206.13.20.pdf						
IA	https://covidtesting.shl.uiowa.edu/							
	https://www.coronavirus.kdheks.gov/DocumentCenter/View/393/COVID-19-Testing-Approval-							
KS	Form-fillable-PDF4-21-20							
	https://chfs.ky.gov/agencies/dph/covid19/guidan							
	https://chfs.ky.gov/Pages/search.aspx?t	tohealthcareproviders regarding COVID 19 state labora						
KY	erms=covid+test&affiliateId=CHFS	torytesting03102020.pdf						
LA	http://ldh.la.gov/assets/oph/Coronavirus/resources/TestingIsolationGuidelines.pdf							
	https://www.maine.gov/tools/whatsnew/index.php?topic=DHS+Press+Releases&id=2657874&							
ME	v=dhhs article 2020							
MD	https://phpa.health.maryland.gov/Docume	ents/coronavirus testing FAQ.pdf						
MA	https://www.mass.gov/info-details/about-	-covid-19-testing#should-i-be-tested?-						
MI	https://www.michigan.gov/coronavirus/0,	9753,7-406-98163-530157,00.html						
MN	https://www.health.state.mn.us/diseases/	coronavirus/symptoms.html#test						
MS	https://msdh.ms.gov/msdhsite/_static/14,21866,420.html							
МО	https://health.mo.gov/emergencies/ert/alertsadvisories/pdf/update42220.pdf							
MT	https://dphhs.mt.gov/publichealth/cdepi/	diseases/coronavirusmt						
	http://dhhs.ne.gov/Documents/COVID-	https://opid10tactions.com/ife/forms						
	19%20Guidance%20to%20Public%20and	https://covid19testingne.co1.qualtrics.com/jfe/form						
NE	%20Testing.pdf	/SV_cJa8ezYYRQfZRCI						

NV	https://nvhealthresponse.nv.gov/find-covid-19-testing-in-nevada/							
NH	https://business.nh.gov/DOS_COVID19Testing/							
NJ	https://covid19.nj.gov/pages/testing							
NM	https://cv.nmhealth.org/public-health-screening-and-testing/location-details/							
NY	https://coronavirus.health.ny.gov/covid-19-testing							
NC	https://covid19.ncdhhs.gov/about-covid-19/testing							
	https://www.health.nd.gov/sites/www/files/documents/Files/MSS/coronavirus/2020 6 16 CO							
ND	VID PCR Guidance.pdf							
ОН	https://coronavirus.ohio.gov/wps/portal/gov/covid-19/families-and-individuals/MHSF/							
	https://coronavirus.health.ok.gov/articles/criteria-guide-evaluation-and-laboratory-testing-							
ОК	covid-19-clinicians-and-laboratories							
OR	https://sharedsystems.dhsoha.state.or.us/DHSForms/Served/le2267.pdf							
PA	https://www.health.pa.gov/topics/disease/coronavirus/Pages/Guidance/Testing-Factsheet.aspx							
RI	https://health.ri.gov/covid/testing/							
	https://www.scdhec.gov/sites/default/files/media/document/10466-DHU-06-19-2020-COVID-							
SC	<u>19.pdf</u>							
SD	https://doh.sd.gov/documents/COVID19/COVID_TestingFacts.pdf							
TN	https://www.tn.gov/governor/covid-19/get-tested.html							
TX	https://dshs.texas.gov/coronavirus/public-health.aspx							
	https://coronavirus-							
	download.utah.gov/Health/UDOH%20HAN%20COVID 04142020 Statewide Guidance%20(1).p							
UT	<u>df</u>							
VT	https://www.healthvermont.gov/response/coronavirus-covid-19/testing-covid-19							

	https://www.vdh.virginia.gov/coronavirus/health-professionals/vdh-updated-guidance-on-							
VA	testing-for-covid-19/							
	https://www.doh.wa.gov/Emergencies/	https://www.doh.wa.gov/Portals/1/Documents/160						
	NovelCoronavirusOutbreak2020COVID19	<u>0/coronavirus/Interim-</u>						
WA	/TestingforCOVID19	2019 Novel Coronavirus Quick sheet Providers. pdf						
WV	https://dhhr.wv.gov/COVID-19/pages/testing.aspx							
WI	https://www.dhs.wisconsin.gov/covid-19/testing.htm							
WY	https://health.wyo.gov/department-offers	-testing-update-advice-for-wyoming/						

232

Figure 1. COVID-19 testing guidelines by state. Testing recommendations for the general public was scaled as follows: 0 = criterion not included, 1 = negative influenza test required, 2 = all symptomatic people, 3 = all people, including asymptomatic people. Testing guidelines for special risk groups are shown in Supplemental Figure 1.

	Mar	Apr	Мау	Jun	Jul		Mar	Apr	Мау	Jun	Jul
AL	2	0	0	0	0	MO	0	0	0	0	3
AK	2	2	2	2	2	MT	2	0	2	2	2
ΑZ	0	0	2	0	0	NE	0	0	2	2	3
AR	2	2	2	2	2	NV	0	0	3	3	3
CA	2	2	3	2	2	NH	0	0	3	3	3
CO	2	2	2	2	2	NJ	2	0	2	3	3
CT	0	2	2	2	2	NM	2	2	2	3	3
DE	0	2	2	3	3	NY	1	1	2	3	3
DC	0	2	2	2	2	NC	1	1	2	2	2
FL	0	2	2	2	2	ND	0	2	2	2	2
GA	0	2	3	3	3	OH	0	0	0	0	3
HI	0	0	0	2	2	OK	0	0	0	0	0
ID	2	0	2	2	2	OR	0	2	2	2	2
IL.	0	0	0	0	0	PA	0	2	2	2	3
IN	0	0	0	0	3	RI	0	2	2	2	2
Α	0	0	0	0	0	SC	0	1	2	2	2
KS	1	0	0	0	0	SD	0	0	0	0	0
ΚY	2	0	0	0	0	TN	0	2	3	3	3
LA	1	2	2	2	2	TX	0	2	2	2	2
ME	2	0	0	2	2	UT	0	2	2	2	2
MD	2	0	2	2	3	VT	2	2	3	3	3
MA	0	0	0	2	2	VA	1	2	2	2	2
MI	0	0	2	2	2	WA	The Contract of the Contract o	2	2	2	2
MN	0	0	2	2	2	WV	1	2	3	3	3
MS	2	0	2	2	2	WI	0	0	2	2	2
						WY	1	0	2	2	2

Figure 2. COVID-19 tests per 1000 population in the United States (A), and the percentage of positive COVID-19 tests (B), March-July 2020. Each state has a line; colors of lines are determined by geographic region per the inserted map.




Figure 3. COVID-19 testing recommendation scores (A) and COVID-19 tests per 1000 people (B) from March-July, 2020 in the United States




Figure 4. Association between the rate of testing for SARS-CoV-2 (per capita) and the completeness of death reporting, as measured by the ratio between reported COVID-19 deaths and excess deaths due to pneumonia/influenza/coronavirus (PIC). The line +/- 95% confidence intervals represents the trend as estimated from a generalized additive model. The size of the circles is proportional to the number of excess deaths due to PIC in each state. The color depicts the month (March-July)—earlier months are darker colors, later months are lighter.

